SCHEMBL24976308

SCHEMBL24976308

CC(=O)N(CC(C)C)c1ccc(-c2ccc(C(=O)NCc3cccnc3)cn2)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 3/20 0.51
▸ EIF4E P06730 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ HPGDS O60760 1/20 0.45
▸ LMNA P02545 6/20 0.44
▸ HTT P42858 5/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ GFER P55789 1/20 0.44
▸ MAPK1 P28482 1/20 0.43
▸ ACACB O00763 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29801118 1.00 NAMPT (0.51) NAMPTEIF4EPOLBHPGDHPGDS
SCHEMBL24975327 0.93 EIF4E (0.45) NAMPTEIF4EPOLBHPGDHPGDS
SCHEMBL29801044 0.93 EIF4E (0.45) NAMPTEIF4EPOLBHPGDHPGDS
SCHEMBL29801266 0.91 POLB (0.46) NAMPTPOLBHPGDHPGDSLMNA
SCHEMBL24975550 0.91 POLB (0.46) NAMPTPOLBHPGDHPGDSLMNA
SCHEMBL24975321 0.91 NAMPT (0.49) NAMPTEIF4EHPGDSLMNAHTT
SCHEMBL29801142 0.91 NAMPT (0.49) NAMPTEIF4EHPGDSLMNAHTT
SCHEMBL24975149 0.89 NAMPT (0.51) NAMPTEIF4EHPGDSLMNAHTT
SCHEMBL29800935 0.89 NAMPT (0.51) NAMPTEIF4EHPGDSLMNAHTT
SCHEMBL24975323 0.88 POLB (0.46) NAMPTEIF4EPOLBHPGDHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2023-01-26 — — US disclosed
CN-114929672-A Cancer therapy targeting cancer stem cells 治疗方案股份有限公司 2022-08-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS MCL1, KIT, GLI1 NAMPT 2789/4885EIF4E 2637/4885POLB 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback